UBS cuts CVS Health target to $118; backs Thyme Care funding
UBS trimmed its price target on CVS Health to $118 from $126. CVS is also investing in Thyme Care’s $125M+ Series E, valuing the startup above $2B.
UBS lowered its price target on CVS Health Corporation (NYSE:CVS) to $118 from $126, according to the source section. The same section says CVS Health Corporation is deepening its health-care bets by investing in Thyme Care’s $125M+ Series E, which values the startup above $2B.